Nektar Therapeutics (NASDAQ:NKTR) COO John Nicholson sold 5,982 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $38.25, for a total value of $228,811.50. Following the completion of the sale, the chief operating officer now owns 174,477 shares in the company, valued at $6,673,745.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Nektar Therapeutics stock traded down $0.22 on Monday, reaching $38.01. 2,486,195 shares of the company’s stock were exchanged, compared to its average volume of 3,133,722. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of -69.11 and a beta of 2.91. Nektar Therapeutics has a 52 week low of $33.50 and a 52 week high of $111.36. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.80 and a current ratio of 13.93.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.07. The firm had revenue of $27.80 million for the quarter, compared to analysts’ expectations of $26.08 million. Nektar Therapeutics had a return on equity of 79.66% and a net margin of 59.71%. The company’s revenue for the quarter was down 81.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.37 EPS. On average, equities research analysts forecast that Nektar Therapeutics will post 3.66 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC acquired a new position in shares of Nektar Therapeutics during the second quarter worth approximately $142,000. Sterling Investment Advisors Ltd. acquired a new position in shares of Nektar Therapeutics during the third quarter worth approximately $183,000. Raymond James Financial Services Advisors Inc. raised its position in shares of Nektar Therapeutics by 68.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 4,290 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 1,747 shares during the period. Gabelli Funds LLC acquired a new position in shares of Nektar Therapeutics during the third quarter worth approximately $213,000. Finally, Laurion Capital Management LP acquired a new position in shares of Nektar Therapeutics during the third quarter worth approximately $219,000. Hedge funds and other institutional investors own 91.42% of the company’s stock.

A number of research firms have issued reports on NKTR. ValuEngine cut Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday. TheStreet cut Nektar Therapeutics from a “c” rating to a “d+” rating in a report on Wednesday, November 7th. HC Wainwright set a $47.00 price target on Nektar Therapeutics and gave the stock a “hold” rating in a report on Monday, November 12th. Canaccord Genuity cut their price target on Nektar Therapeutics from $94.00 to $86.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Finally, Cowen restated a “buy” rating and set a $86.00 price target on shares of Nektar Therapeutics in a report on Thursday, November 8th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Nektar Therapeutics currently has an average rating of “Hold” and an average target price of $85.78.

TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NKTR) COO John Nicholson Sells 5,982 Shares” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/19/nektar-therapeutics-nktr-coo-john-nicholson-sells-5982-shares.html.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Featured Story: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.